Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.

CONCLUSIONS: Ziprasidone as an adjunct to escitalopram demonstrated antidepressant efficacy in adult patients with major depressive disorder experiencing persistent symptoms after 8 weeks of open-label treatment with escitalopram. PMID: 26085041 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26085041?dopt=Abstract

Source: The American Journal of Psychiatry - June 18, 2015 Category: Psychiatry Authors: Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC Tags: Am J Psychiatry Source Type: research